** U.S. generic drugmaker Akorn < AKRX.O > is taking former suitor Fresenius to court after the German healthcare group cancelled their $ 4.75 billion takeover agreement. (reuters.com)
Shire has long been seen as a likely takeover target and was nearly bought by U.S. drugmaker AbbVie in 2014, until U.S. tax rule changes caused it to walk away. (reuters.com)
Capital Markets M&A Pharmaceuticals In what could become Israel's biggest cross-border M&A deal ever, Teva Pharmaceutical Industries made an unsolicited $ 40 billion offer to acquire Mylan, a Pennsylvania - based drugmaker registered in the Netherlands with operational headquarters in the UK. (gfmag.com)